23.05.2008 12:00:00
|
DexCom Appoints Jonathan Lord, M.D. as Board Member
DexCom Inc. (NASDAQ:DXCM) today announced the appointment of Jonathan T.
Lord, M.D. as a member of DexCom’s Board of
Directors.
Dr. Lord currently serves as Senior Vice President and Chief Innovation
Officer for Humana Inc., a health benefits company. Dr. Lord joined
Humana in 2000 to help develop the company's consumer-centric business
strategy. In his role as Chief Innovation Officer, Dr. Lord is
responsible for designing innovative health plan products and leading
processes that enable people to navigate the healthcare system and
support their health needs.
Dr. Lord created Humana's Innovation Center, a functional blend of
research, (including consumer research, outcomes research, and
predictive science), product design, and consumer experience engineering
that is unique to the health benefits industry. Dr. Lord’s
work has led to industry-leading products, patent-pending innovations in
predictive science, and an aggressive entrepreneurship taking the
company into global business relationships. In 2006, Dr. Lord began
leading Humana's efforts to establish Humana Europe.
"Jack is one of the most respected and successful business leaders in
the medical field. We recruited Jack to the board of directors for the
wealth of experience and success he has had in driving rapid commercial
growth during his career and innovating new products in the competitive
healthcare landscape," said Terry Gregg, President and Chief Executive
Officer of DexCom.
With 16 years experience in medical administration, he joined Humana
from Health Dialog, a Boston-based Internet provider of health
information to more than 5 million Americans, where he served as
president and became a leader in e-enabled healthcare. Prior to joining
Health Dialog, he served as chief operating officer of the American
Hospital Association in Washington, D.C., executive vice president of
Anne Arundel Medical Center in Annapolis, MD, and executive vice
president of Sun Health in Charlotte, NC.
A board-certified forensic pathologist, Dr. Lord began his medical
career in the U.S. Navy, where he spent 11 years on active duty, most
recently as director of the Naval Medical Command's Quality Assurance
Division in the Office of the Surgeon General. He also served as a
consultant and surveyor for the Joint Commission on Accreditation of
Health Care Organizations.
About DexCom, Inc.
DexCom, Inc., headquartered in San Diego, California, is developing and
marketing continuous glucose monitoring systems for people with diabetes.
Cautionary Statement Regarding Forward Looking Statements
DexCom is a medical device company with a limited operating history.
Successful commercialization of the company’s
products is subject to numerous risks and uncertainties, including a
lack of acceptance in the marketplace by physicians and patients, the
inability to manufacture products in commercial quantities at an
acceptable cost, possible delays in the company’s
development programs, the inability of patients to receive
reimbursements from third-party payors and inadequate financial and
other resources. Certain of these risks and uncertainties, in addition
to other risks, are more fully described in the company’s
quarterly report on Form 10-Q for the period ending March 31, 2008, as
filed with the Securities and Exchange Commission on May 8, 2008.
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
JETZT DEVISEN-CFDS MIT BIS ZU HEBEL 30 HANDELN
Handeln Sie Devisen-CFDs mit kleinen Spreads. Mit nur 100 € können Sie mit der Wirkung von 3.000 Euro Kapital handeln.
82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren.
Nachrichten zu DexCom Inc.mehr Nachrichten
10.12.24 |
NASDAQ Composite Index-Papier DexCom-Aktie: So viel hätten Anleger an einem DexCom-Investment von vor 3 Jahren verloren (finanzen.at) | |
06.12.24 |
NASDAQ-Handel: NASDAQ 100 klettert (finanzen.at) | |
06.12.24 |
Optimismus in New York: NASDAQ 100 am Freitagmittag mit Zuschlägen (finanzen.at) | |
03.12.24 |
NASDAQ 100 aktuell: NASDAQ 100 liegt letztendlich im Plus (finanzen.at) | |
03.12.24 |
NASDAQ Composite Index-Titel DexCom-Aktie: So viel hätten Anleger mit einem Investment in DexCom von vor einem Jahr verloren (finanzen.at) | |
26.11.24 |
NASDAQ Composite Index-Wert DexCom-Aktie: So viel hätten Anleger mit einem Investment in DexCom von vor 10 Jahren verdient (finanzen.at) | |
25.11.24 |
NASDAQ-Handel: NASDAQ 100 notiert letztendlich im Plus (finanzen.at) | |
22.11.24 |
NASDAQ-Handel: NASDAQ 100 letztendlich mit Kursplus (finanzen.at) |
Analysen zu DexCom Inc.mehr Analysen
Aktien in diesem Artikel
DexCom Inc. | 75,32 | 0,08% |
Indizes in diesem Artikel
NASDAQ Comp. | 19 687,24 | -0,25% |